// App-Quantinova.ai

TPS6091 : TrilynX: A phase 3 trial of xevinapant and concurrent chemoradiation for locally advanced head and neck cancer.

Researchers

Presenter

  • Jean Bourhis

Principal Investigators

  • Barbara Burtness

  • Lisa F. Licitra

  • Christopher Nutting

  • Jonathan D. Schoenfeld

  • Rafik Ait Sarkouh

  • Florilene Bouisset

  • Heidi Nauwelaerts

  • Yulia Urfer

  • Claudio Zanna

  • Ezra E.W. Cohen

Medical Centers

  • Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland

  • Yale School of Medicine, Smilow Cancer Center, New Haven, CT

  • Fondazione IRCCS Istituto Nazionale dei Tumori and University of Milan, Milan, Italy

  • The Royal Marsden Hospital NHS Foundation Trust, London & Surrey, United Kingdom

  • Dana-Farber Cancer Institute, Boston, MA

  • Debiopharm International SA, Lausanne, Switzerland

  • University of California, San Diego, La Jolla, CA

Locations

  • Switzerland

  • United States

  • Italy

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Squamous cell carcinoma of the head and neck

Biomarkers

  • Aspartate aminotransferase

  • Alanine transaminase

Drug/Treatment

  • Cisplatin

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Double Blind/Blinded

  • Multinational

  • Controlled

Phase

  • III

Study Id's

  • NCT04459715

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved